MeSH term
Frequency | Condition_Probility | Humans | 187 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Enzyme Activation | 24 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
Neuregulin-1/*physiology | 4 | 44.0 |
Receptor, erbB-2/*metabolism | 22 | 14.0 |
Research Support, U.S. Gov't, P.H.S. | 88 | 0.0 |
Tumor Cells, Cultured | 56 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Cell Division/drug effects | 15 | 0.0 |
Enzyme Inhibitors/pharmacology | 10 | 0.0 |
Epidermal Growth Factor/*pharmacology | 5 | 0.0 |
Growth Substances/pharmacology | 2 | 1.0 |
*Intercellular Signaling Peptides and Proteins | 4 | 0.0 |
Ligands | 28 | 1.0 |
Neuregulin-1/pharmacology | 7 | 46.0 |
Phosphorylation | 46 | 0.0 |
*Protein-Serine-Threonine Kinases | 7 | 0.0 |
Proto-Oncogene Proteins/metabolism | 16 | 1.0 |
Receptor, Epidermal Growth Factor/*antagonists & inhibitors | 2 | 1.0 |
Receptor, erbB-2/*antagonists & inhibitors | 2 | 13.0 |
Research Support, Non-U.S. Gov't | 127 | 0.0 |
Cell Line | 29 | 0.0 |
Dimerization | 16 | 1.0 |
Receptor, Epidermal Growth Factor/*metabolism | 25 | 3.0 |
Receptor, erbB-2/*physiology | 7 | 28.0 |
Receptor, erbB-3/*physiology | 3 | 60.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 16 | 0.0 |
Signal Transduction | 27 | 0.0 |
Tyrosine/*metabolism | 3 | 0.0 |
Adult | 18 | 0.0 |
Female | 62 | 0.0 |
Gene Expression | 6 | 0.0 |
Neuroblastoma/genetics | 2 | 8.0 |
Receptor, erbB-3/genetics | 2 | 66.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Sarcoma, Ewing's/genetics | 2 | 18.0 |
Amino Acid Sequence | 36 | 0.0 |
Kinetics | 9 | 0.0 |
Models, Molecular | 6 | 0.0 |
Molecular Sequence Data | 43 | 0.0 |
Protein Conformation | 5 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/metabolism | 2 | 28.0 |
Receptor, erbB-2/chemistry/metabolism | 2 | 66.0 |
Receptor, erbB-3/chemistry/metabolism | 2 | 100.0 |
Immunohistochemistry/methods | 7 | 1.0 |
Prognosis | 8 | 0.0 |
Receptor, erbB-2/*analysis | 3 | 3.0 |
Survival Analysis | 3 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Male | 34 | 0.0 |
Middle Aged | 20 | 0.0 |
Receptor, erbB-3/*metabolism | 12 | 57.0 |
Aged | 17 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Blotting, Western | 17 | 0.0 |
Receptor, Epidermal Growth Factor/analysis | 4 | 2.0 |
Receptor, erbB-3/*analysis | 3 | 60.0 |
Animals | 81 | 0.0 |
COS Cells | 3 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Neuregulins/*metabolism | 3 | 75.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Receptor, erbB-2/metabolism | 19 | 11.0 |
Receptor, erbB-3/genetics/*metabolism | 3 | 100.0 |
Amino Acid Motifs | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Gene Library | 2 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Precipitin Tests | 8 | 0.0 |
Protein Binding | 16 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Tyrosine/metabolism | 15 | 1.0 |
src Homology Domains | 4 | 0.0 |
*Genes, erbB | 4 | 36.0 |
*Genes, erbB-2 | 4 | 4.0 |
Insulin/*pharmacology | 2 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
*ADP Ribose Transferases | 2 | 2.0 |
*Bacterial Toxins | 2 | 1.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 23 | 4.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Time Factors | 7 | 0.0 |
*Virulence Factors | 2 | 2.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Breast Neoplasms | 5 | 1.0 |
Cell Division/physiology | 2 | 0.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Phthalimides/pharmacology | 2 | 100.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*metabolism | 2 | 6.0 |
Receptor, erbB-2/genetics/*metabolism | 4 | 12.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
CHO Cells | 5 | 0.0 |
Cell Line, Tumor | 12 | 0.0 |
Hamsters | 7 | 0.0 |
In Vitro | 6 | 0.0 |
Oncogene Proteins v-erbB/metabolism | 3 | 33.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/*metabolism | 4 | 2.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 3 | 5.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Receptors, Muscarinic/*physiology | 2 | 9.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Comparative Study | 26 | 0.0 |
Neoplasm Invasiveness | 5 | 0.0 |
Receptor, erbB-2/analysis | 2 | 2.0 |
Cell Cycle | 4 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Drosophila | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Mice | 37 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
Receptor, erbB-3/*chemistry | 2 | 66.0 |
Transfection | 20 | 0.0 |
Ubiquitin/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 5 | 0.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Blotting, Northern | 9 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Heparin/metabolism | 2 | 1.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Mammary Glands, Animal/*metabolism | 2 | 10.0 |
Signal Transduction/*physiology | 8 | 0.0 |
Cohort Studies | 2 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Receptor, erbB-2/*biosynthesis | 4 | 8.0 |
Receptor, erbB-3/*biosynthesis | 3 | 50.0 |
Databases, Factual | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Protein Isoforms | 5 | 0.0 |
Solubility | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 5 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 11 | 1.0 |
*Signal Transduction | 11 | 0.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
*Gene Expression Profiling | 2 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Tissue Distribution | 4 | 0.0 |
3T3 Cells | 7 | 0.0 |
Phosphorylation/drug effects | 6 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 6 | 0.0 |
Antibodies/immunology | 2 | 0.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Receptor, erbB-3/metabolism | 16 | 55.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Cells, Cultured | 17 | 0.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Rats | 24 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Up-Regulation | 6 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 4 | 1.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Down-Regulation | 5 | 0.0 |
Estrogen Antagonists/pharmacology | 2 | 2.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
*Gene Expression | 4 | 0.0 |
Genes, erbB-1 | 2 | 11.0 |
Genes, erbB-2 | 3 | 3.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Adolescent | 5 | 0.0 |
Base Sequence | 18 | 0.0 |
DNA Primers | 6 | 0.0 |
Receptor, erbB-2/*genetics | 3 | 8.0 |
Central Nervous System Depressants/*pharmacology | 2 | 12.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*metabolism | 3 | 13.0 |
Cell Survival/drug effects | 4 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Cell Communication | 2 | 0.0 |
Coculture Techniques | 3 | 0.0 |
Models, Neurological | 2 | 1.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Neuregulin-1/*metabolism | 4 | 28.0 |
Cell Differentiation/genetics | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/*genetics | 3 | 1.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Signal Transduction/genetics | 3 | 1.0 |
Cell Differentiation | 4 | 0.0 |
Cell Division | 14 | 0.0 |
Cell Separation | 2 | 0.0 |
Phenotype | 2 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Binding Sites | 12 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Rabbits | 3 | 0.0 |
Androstadienes/pharmacology | 4 | 1.0 |
Blotting, Southern | 4 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 6 | 1.0 |
Epidermal Growth Factor/*metabolism | 4 | 1.0 |
Breast Neoplasms/*metabolism | 5 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Cell Count/drug effects | 2 | 2.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Neuregulin-1/metabolism | 2 | 15.0 |
Alternative Splicing | 2 | 0.0 |
Oncogene Proteins v-erbB/*metabolism | 2 | 33.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Cell Cycle/drug effects | 5 | 0.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Breast Neoplasms/metabolism/*pathology | 2 | 2.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/metabolism | 2 | 2.0 |
Receptor, erbB-2/chemistry/drug effects/*physiology | 2 | 100.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Spodoptera | 2 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Bladder/cytology/*metabolism/pathology | 2 | 66.0 |
Epidermal Growth Factor/genetics/metabolism/*physiology | 2 | 40.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mitogens/pharmacology | 3 | 1.0 |
Muscle, Smooth/cytology/*metabolism/pathology | 2 | 100.0 |
Urethral Obstruction/*metabolism/pathology | 2 | 100.0 |
DNA/biosynthesis | 3 | 0.0 |
Receptor, Epidermal Growth Factor/*physiology | 2 | 1.0 |
Androgens/metabolism | 2 | 3.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Epidermal Growth Factor/metabolism | 5 | 1.0 |
Glycoproteins/*pharmacology | 7 | 7.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Neuregulins | 13 | 22.0 |
Protein-Tyrosine Kinase/metabolism | 6 | 0.0 |
Receptor, erbB-3 | 36 | 41.0 |
Retinoblastoma Protein/metabolism | 3 | 0.0 |
Cytoplasm/enzymology | 2 | 2.0 |
Sequence Analysis, DNA | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/*metabolism | 4 | 11.0 |
Cell Division/genetics | 2 | 0.0 |
*Adaptor Proteins, Signal Transducing | 5 | 0.0 |
Proteins/metabolism | 4 | 0.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Proto-Oncogene Proteins/chemistry/*metabolism | 2 | 3.0 |
*Neuregulin-1 | 17 | 65.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Proteoglycans | 2 | 2.0 |
Carrier Proteins/chemistry/*metabolism | 2 | 2.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Glycoproteins/chemistry/*metabolism | 2 | 16.0 |
Cluster Analysis | 2 | 1.0 |
Gene Expression Profiling | 3 | 0.0 |
Genes, erbB/*genetics | 2 | 66.0 |
Receptor, erbB-3/biosynthesis/genetics | 2 | 100.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Receptor, erbB-2/biosynthesis/*genetics | 2 | 28.0 |
Carrier Proteins/*metabolism | 5 | 0.0 |
Glycoproteins/*metabolism | 5 | 2.0 |
Child | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Receptor, erbB-2/genetics/metabolism | 3 | 20.0 |
Receptor, erbB-3/genetics/metabolism | 3 | 75.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 4 | 1.0 |
Survival Rate | 3 | 0.0 |
Antibodies | 2 | 0.0 |
Carrier Proteins/*pharmacology | 4 | 8.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Risk Factors | 2 | 0.0 |
*Protein Conformation | 3 | 1.0 |
Peptide Mapping | 2 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/drug effects/metabolism | 2 | 7.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Trans-Activators/drug effects/metabolism | 2 | 9.0 |
Transplantation, Heterologous | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
PC12 Cells | 2 | 0.0 |
Breast/metabolism | 2 | 2.0 |
Organ Specificity | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/chemistry/metabolism | 2 | 8.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*genetics/metabolism | 2 | 3.0 |
Genes, erbB | 5 | 62.0 |
Sequence Alignment | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 7 | 4.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 4 | 4.0 |
Thymidine/metabolism | 3 | 0.0 |
Protein Folding | 2 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Receptor Aggregation | 2 | 2.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 3 | 5.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 3 | 4.0 |
Restriction Mapping | 2 | 0.0 |
Glycoproteins/physiology | 2 | 6.0 |
Molecular Weight | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Phosphotyrosine | 4 | 1.0 |
Tyrosine/analogs & derivatives/metabolism | 3 | 2.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Immunologic Techniques | 2 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Antineoplastic Agents/pharmacology/therapeutic use | 2 | 6.0 |
*Proto-Oncogenes | 2 | 0.0 |
Neuregulin-1/*pharmacology | 3 | 17.0 |
RNA, Small Interfering/pharmacology | 2 | 2.0 |
Receptor, Epidermal Growth Factor/genetics | 2 | 1.0 |
Receptor Cross-Talk/*physiology | 2 | 15.0 |
Gene Deletion | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*genetics | 2 | 0.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Neuregulin-1/genetics/*metabolism | 2 | 100.0 |
Crystallography, X-Ray | 3 | 0.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |